Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Update analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer (148P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Takeshi Yamada

Citation

Annals of Oncology (2017) 28 (suppl_10): x42-x56. 10.1093/annonc/mdx659

Authors

T. Yamada1, Y. Kito2, H. Satake3, H. Taniguchi4, Y. Horie5, T. Esaki6, T. Denda7, K. Mori8, K. Yamazaki9

Author affiliations

  • 1 Division Of Gastroenterology, University of Tsukuba, 305-8575 - Tsukuba/JP
  • 2 Department Of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa/JP
  • 3 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 4 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 5 Department Of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki/JP
  • 6 Department Of Gastrointestinal And Medical Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 7 Division Of Gastroenterology, Chiba Cancer Center Hospital, 260-8717 - Chiba/JP
  • 8 Clinical Research Center, Shizuoka Cancer Center, Sunto-gun/JP
  • 9 Gastroenterology, Surgery, Oncology, Shizuoka Cancer Center, 411-8777 - Sunto-gun/JP
More

Resources

Background

Ramucirumab (Rmab), an anti-VEGFR-2 antibody, inhibits VEGF-A, -C, -D binding and endothelial cell proliferation, although bevacizumab binds to and blocks circulating VEGF-A. We had presented the result of dose finding phase Ib study of FOLFOXIRI plus Rmab for metastatic colorectal cancer (mCRC) patients (pts) in the 19th World Congress on Gastrointestinal Cancer. Here we reported the update analysis.

Methods

The eligibility criteria included pts with unresectable colorectal adenocarcinoma, 20-75 years, ECOG PS 0-1 (pts > 70 years were eligible if their ECOG PS was 0), wild-type or heterozygous UGT1A1 *28 or *6, no history of prior chemotherapy, and adequate organ function. Three dose levels were planned as follows: oxaliplatin and Rmab dose was fixed at 85 mg/m2 and 8 mg/kg, respectively. Level 1: 5-fluorouracil (5-FU) 3200 mg/m2, irinotecan (IRI) 165 mg/m2, Level 0 as starting dose: 5-FU 2400 mg/m2, IRI 150 mg/m2, and Level -1: 5-FU 2400 mg/m2, IRI 120 mg/m2. The dose-limiting toxicity (DLT) was evaluated in the first cycle.

Results

We enrolled a total of 10 pts (4 pts in the Level 0 and 6 pts in the Level 1). The pts characteristics were as follows: median age, 64 (range, 44-68); male/female, 6/4; ECOG PS 0/1, 8/2; RAS wild/mutant, 1/9; UGT1A1 *1*1/*1*28, 4/6. One patient was excluded for the DLT evaluation due to lack of safety evaluation on cycle 1 day 8. No DLT was observed in the 9 DLT-evaluable pts. Among 8 pts who had at least one tumor evaluation, early tumor shrinkage, response rate and disease control rate was 87.5%, 75% and 100%, respectively. In the first 3-cycle, major adverse events were Grade (G) 4 neutropenia (n = 2), G3 neutropenia (n = 1), G3 hypertension (n = 2), G2 thrombocytopenia (n = 4), G2 anorexia (n = 3), G2 hypertension (n = 3), G2 fatigue (n = 2) and G2 proteinurea (n = 2). G-CSF was administered in 2 pts in the first cycle.

Conclusions

FOLFOXIRI plus Rmab showed a promising antitumor activity with acceptable toxicity, although this study had a small sample size. A randomized phase II study of FOLFIRI plus Rmab versus FOLFOXIRI plus Rmab (Level 1) for chemotherapy-naïve mCRC pts (WJOG9216G trial; UMIN000026527) is on-going.

Clinical trial identification

UMIN000023277.

Legal entity responsible for the study

Shizuoka Cancer Center

Funding

Shizuoka Cancer Center

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings